Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519373 | 0.86 | CNR1 (0.41) | PLA2G1BATG4BTRPA1PSMB5PSMB1 | |
| SCHEMBL15801416 | 0.85 | TRPA1 (0.52) | TLR7TRPA1RAB9ASMN1; SMN2 | |
| SCHEMBL15520200 | 0.81 | SMN1; SMN2 (0.52) | PLA2G1BATG4BTRPA1PSMB5PSMB1 | |
| SCHEMBL23851592 | 0.80 | PRPS1 (0.46) | TLR7 | |
| SCHEMBL15519761 | 0.79 | FSCN1 (0.40) | PLA2G1BATG4BPSMB5PSMB1RAB9A | |
| SCHEMBL15519964 | 0.77 | MAPK1 (0.40) | PLA2G1BATG4BTRPA1PSMB5PSMB1 | |
| SCHEMBL15519410 | 0.76 | KDM4E (0.48) | TLR7PLA2G1BATG4BRAB9ASMN1; SMN2 | |
| SCHEMBL15519807 | 0.76 | RAB9A (0.44) | RAB9ASMN1; SMN2 | |
| SCHEMBL15519299 | 0.75 | RAB9A (0.40) | PLA2G1BATG4BRAB9ASMN1; SMN2 | |
| SCHEMBL15518945 | 0.75 | CNR1 (0.41) | TLR7PLA2G1BATG4BTRPA1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708540-B1 | PYRIMIDO-DIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9453021-B2 | Pyrimidodiazepinone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2708540-A1 | PYRIMIDO-DIAZEPINONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | TLR7 1432/4885PLA2G1B 4286/4885ATG4B 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.